Framework to Construct and Interpret Latent Class Trajectory Modelling
Overview
Authors
Affiliations
Objectives: Latent class trajectory modelling (LCTM) is a relatively new methodology in epidemiology to describe life-course exposures, which simplifies heterogeneous populations into homogeneous patterns or classes. However, for a given dataset, it is possible to derive scores of different models based on number of classes, model structure and trajectory property. Here, we rationalise a systematic framework to derive a 'core' favoured model.
Methods: We developed an eight-step framework: step 1: a scoping model; step 2: refining the number of classes; step 3: refining model structure (from fixed-effects through to a flexible random-effect specification); step 4: model adequacy assessment; step 5: graphical presentations; step 6: use of additional discrimination tools ('degree of separation'; Elsensohn's envelope of residual plots); step 7: clinical characterisation and plausibility; and step 8: sensitivity analysis. We illustrated these steps using data from the NIH-AARP cohort of repeated determinations of body mass index (BMI) at baseline (mean age: 62.5 years), and BMI derived by weight recall at ages 18, 35 and 50 years.
Results: From 288 993 participants, we derived a five-class model for each gender (men: 177 455; women: 111 538). From seven model structures, the favoured model was a proportional random quadratic structure (model F). Favourable properties were also noted for the unrestricted random quadratic structure (model G). However, class proportions varied considerably by model structure-concordance between models F and G were moderate (Cohen κ: men, 0.57; women, 0.65) but poor with other models. Model adequacy assessments, evaluations using discrimination tools, clinical plausibility and sensitivity analyses supported our model selection.
Conclusion: We propose a framework to construct and select a 'core' LCTM, which will facilitate generalisability of results in future studies.
Huang Y, Ainiwan D, Qiu Y, Zhang L, Alifu X, Cheng H Nutr Diabetes. 2025; 15(1):10.
PMID: 40075061 PMC: 11904208. DOI: 10.1038/s41387-025-00365-y.
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.
Pan X, Zhou Y, Li Z, Guo P, Zeng J, Dong X Commun Med (Lond). 2025; 5(1):65.
PMID: 40050645 PMC: 11885828. DOI: 10.1038/s43856-025-00784-z.
Wang J, Yang Y, Wu J, Xie T, Guo X, Yuan X BMC Public Health. 2025; 25(1):341.
PMID: 39871252 PMC: 11773840. DOI: 10.1186/s12889-025-21487-z.
Dragoi I, Rezus C, Burlui A, Bratoiu I, Rezus E Medicina (Kaunas). 2025; 61(1).
PMID: 39859001 PMC: 11766816. DOI: 10.3390/medicina61010019.
Tindal K, Cousins F, Palmer K, Ellery S, Vollenhoven B, Gargett C BMJ Open. 2025; 15(1):e091813.
PMID: 39843375 PMC: 11784170. DOI: 10.1136/bmjopen-2024-091813.